Search results

*****************************************************************************************

*****************************************************************************************

The Army Study to Assess Risk and Resilience in Servicemembers (STARRS) is an extensive study of mental health risk and resilience among military personnel. Army STARRS consists of eight separate but integrated epidemiologic and neurobiologic studies. Survey data for three of the Army STARRS study components are available via Secure Dissemination or via the ICPSR Virtual Data Enclave: New Soldier Study (NSS); All Army Study (AAS) and Pre-Post Deployment Study (PPDS). Also available are data for the STARRS-Longitudinal Study (STARRS-LS), which are follow-up surveys conducted with Army STARRS participants from AAS, NSS and PPDS studies. Lastly, baseline administrative data from the Army/Department of Defense (DoD) and blood sample flags for Soldiers who had blood drawn as a part of their participation in NSS or PPDS are available.

The AAS component of Army STARRS assesses soldiers' psychological and physical health, events encountered during training, combat, and non-combat operations, and life and work experiences across all phases of Army service. The AAS data includes data on soldiers' psychological resilience, mental health, and risk for self-harm.

The NSS data are drawn from new soldiers who have just entered the Army. The data contain information on soldier health, personal characteristics, and prior experiences. Results from a series of neurocognitive tests are also included in the NSS data.

The PPDS data are drawn from active duty soldiers who were interviewed at four points in time: 3-4 months prior to deployment to Afghanistan; within 1-2 weeks after return from deployment; 1-3 months after return from deployment; and 9-12 months after return from deployment. The PPDS data contain information on soldiers' psychological resilience, mental health, deployment experiences, and risk for self-harm.

The STARRS-LS data are from multiple follow-up interviews with individuals who previously participated in the AAS, NSS and PPDS study components of Army STARRS. STARRS-LS data contain follow-up information on soldiers' and veterans' physical and mental health, resilience and risk for self-harm, military and employment status, deployment experience, and personal characteristics as they move through their Army careers and after they leave the Army.

The California Families Project (CFP) is an ongoing longitudinal study of Mexican origin families in Northern California. This study uses community, school, family, and individual characteristics to examine developmental pathways that increase risk for and resilience to drug use in Mexican-origin youth. This study also examines the impact that economic disadvantage and cultural traditions have in Mexican-origin youth. The CFP includes a community-based sample of 674 families and children of Mexican origin living in Northern California, and includes annual assessments of parents and children. Participants with Mexican surnames were drawn at random from school rosters of students during the 2006-2007 and 2007-2008 school year. Data collection included multi-method assessments of a broad range of psychological, familial, scholastic, cultural, and neighborhood factors. Initiation of the research at age 10 was designed to assess the focal children before the onset of Alcohol, Tobacco, and Other Drug (ATOD) use, thus enabling the evaluation of how hypothesized risk and resilience mechanisms operate to exacerbate early onset during adolescence or help prevent its occurrence. This study includes a diversity of families that represent a wide range of incomes, education, family history, and family structures, including two-parent and single-parent families.

The accompanying data file consists of 674 family cases with each case representing a focal child and at least one parent (Two-parent: n=549, 82 percent; Single-parent: n=125, 18 percent). Of the 3,139 total variables, 839 pertain to the focal child, 1,376 correspond to the mother, and 908 items pertain to the father.

Please note: While the California Families Project is a longitudinal study, only the baseline data are currently available in this data collection.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Iowa Adoption Studies were conducted between 1975 and 2008. The group of studies consist of 5 independent waves of data collection each of which examined genetic (biological) and environmental influences on psychopathology. The adoption paradigm allowed separation of genetic and environmental influences on behavior, as well as joint influences due to gene x environment interaction. Adoptees were interviewed about lifetime psychopathology including substance abuse and dependence, antisocial personality, and mood disorders. A follow-up study was conducted from 2000-2004 that recruited all previous participants and natural offspring of the adoptive parents when available. Standardized psychiatric assessments were administered along with measures of personality disorders and traits, retrospective reports on childhood experiences with adoptive parents, and current symptomatology. An extensive neurocognitive assessment was conducted on a subset of participants who had standardized school achievement scores. The goal of this last wave of assessment was to evaluate the influence of substance use on mid-life cognition and health.

The respondents were assessed using a number of different surveys over the study period. The following describes the notable variables as well as descriptions of the surveys included in the dataset.

The first variables in the dataset identify sibling pairs and provides data on whether the respondents' biological parents suffered from mental health or substance abuse issues. Next birth records are provided that give basic information about the health of the person when he or she was born. This information is followed by the survey results of "The Schedule for Nonadaptive and Adaptive Personality" (SNAP) as well as variables that reflect the diagnosis of personality disorders and nonadaptive personality traits based on the SNAP survey responses.

The next section includes responses from "The Iowa Personality Disorder Screen," a quick personality disorder screen developed in 1999 intended for use in clinical and research settings.

Next, responses to Pearson Assessments "Brief symptoms inventory" are included as well as the scores calculated based on these survey responses. The results of this survey assess the mental state of the patient including scales on Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation and Psychoticism.

The respondents also completed the "Buss-Durkee Hostility Questionnaire" and were assessed on measure regarding the following hostility traits: negativism, resentment, indirect hostility, assault, suspicion, irritability and verbal hostility.

Reponses to the "The Social Provisions Scale" survey are also included. The purpose of this survey is to assess the relationship the respondents have to other people. The 6 social provisions assessed include: guidance, reliable alliance, reassurance of worth, attachment, social integration, and opportunity for nurturance.

"The Parental Bonding Instrument" instrument was utilized to assess the respondents' relationships to their mothers and fathers.

A series of cognitive tests were administered to respondents. ICPSR is unable to provide the survey instruments used in the cognitive test due to copy write issues. These tests include:

Controlled Oral Word Association Test (COWAT)

North American Adult Reading Test (NAART)

Rey Figure and Rey Complex Figure Test and Recognition Trial (RCFT)

Shipley Institute of Living Scale (SILS)

Stroop Color and Word Test (SCWT)

Tower of Hanoi (TofH)

Comprehensive Trailmaking Test (CTMT)

Weschler Adult Intelligence Test (WAIS)

Weschler Memory Test (WMS)

The dataset also includes respondents' results of the Comprehensive Performance Test (CPT) and the Iowa Gambling Task (IGT)

Scores from the "Iowa Test of Basic Skills," a test of academic achievement that evaluates students knowledge in subjects including, mathematics, reading comprehension, and science, are included in the dataset. Respondents are evaluated in grades 4, 8 and 11.

The final section of the dataset includes two waves of the "Semi Structured Assessment for the Genetics of Alcoholism," a survey intended to assess the physical, psychological, and social manifestations of alcohol abuse. These survey responses make up the bulk of the dataset and include variables on a variety of topics including: demographics, medical history, substance use, eating disorders, depression, dysthymia, mania, ASP, suicide, PTSD, generalized anxiety disorder, OCD, social phobia, agoraphobia, panic disorder, home environment, gambling, and ADHD. Substances use investigated includes alcohol, tobacco, marijuana, sedatives, stimulants, cocaine, opiates, solvents, hallucinogens, and other drugs.

This dataset includes 934 cases and 9,370 variables.

This data collection contains the first four waves of the Iowa Youth and Families Project (IYFP), conducted in 1989, 1990, 1991, and 1992. The Iowa Youth and Families Project was developed from an initial sample of 451 7th graders from two-parent families in rural Iowa. The study was merged with the Iowa Single Parent Project (ISPP) to form the Iowa Family Transitions Project in 1994, when the target youth were seniors in high school. Survey data were collected from the target child (7th grader), a sibling within four years of age of the target child, and both parents. Field interviewers visited families at their homes on several occasions to administer questionnaires and videotape interaction tasks including family discussion tasks, family problem-solving tasks, sibling interaction tasks, and marital interaction tasks.

The Household Data files contain information about the family's financial situation, involvement in farming, and demographic information about household members.

The Parent and the Child Survey Data files contain responses to survey questions about the quality and stability of family relationships, emotional, physical, and behavioral problems of individual family members, parent-child conflict, family problem-solving skills, social and financial support from outside the home, traumatic life experiences, alcohol, drug, and tobacco use, and opinions on topics such as abortion, parenting, and gender roles. In addition, the Child Survey Data files include responses collected from the target child and his or her sibling in the study about experiences with puberty, dating, sexual activity, and risk-taking behavior.

The Problem-Solving Data files contain survey data collected from respondents about the family interactions tasks.

The Observational Data files contain the interviewers' observations collected during these tasks.

Demographic variables include sex, age, employment status, occupation, income, home ownership, religious preference, frequency of religious attendance, as well as the ages and sex of all household members and their relationship to the head of household. Demographic information collected on the parents also includes their birth order within their family, the ages and political philosophy of their parents, the sex, age, education level, and occupation of their siblings, and the country of origin of their ancestors.

The Johns Hopkins University Prevention Research center - Risks for Transitions, Baltimore city, 2008-2011 study (JHU PRC Risks for Transition in Drug Use among Urban Adults) represents data collected for a 25 years follow-up from the original JHU PRC study. At the start of the data collection, a cohort of 2,311 youth were randomly assigned to two classroom-based universal preventive interventions implemented in 43 classrooms of 19 public schools located in 5 socio-demographically distinct areas in Eastern Baltimore. This collection includes data from 1,434 respondents from the original cohort collected in 2008-2012. The mean age of the respondents was 30-32 years old.

Psychopathology (major depressive episode, phobia and anxiety disorders) was assessed using modules from the Composite International Diagnostic Interview-University of Michigan Version, CIDI- UM (WHO, 1997). An antisocial symptom scale adapted from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC) was administered which consisted of 30 questions that assessed behaviors experienced since turning 18 years of age. The alcohol, tobacco and drug modules of the interview were modeled after NESARC Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV. Types of information in these modules collected include age of onset, use in past year and prior past year, frequency and recency of use, and DSM-IV abuse and dependence criteria. Socioeconomic status indicators, variables on education, employment, marital status, parenthood, social supports, family history of mental health and drug problems, general health, treatment utilization, and life events are included in this dataset.

This dataset includes 3,140 variables.

This study is part of the Seek, Test, Treat and Retain (STTR) Collaboration Project that involved over twenty studies in the fields of HIV and drug abuse. All studies were independently developed, but were chosen for the collaboration because they focused on one or more steps of the HIV treatment cascade: Seek, Test, Treat and Retain. As part of STTR Collaboration Project, the studies were grouped into Criminal Justice-related studies and Vulnerable Population-related studies. The data collected by these studies included twelve common domains (e.g., Demographic characteristics, Mental Health) in each of which a shared questionnaire or instrument was taken up by the studies and adapted to fit the study.

Linking Infectious and Narcology Care (LINC) involved coordination between the narcology and HIV systems of care utilizing HIV strengths-based case management delivered via five one-on-one sessions by a peer case manager (i.e., HIV-infected men and women in recovery from addiction) to help motivate and reduce barriers to HIV care. The initial session was designed to be delivered in the narcology hospital and included provision of CD4 test results by the case manager (CM) in a timely fashion, to increase engagement in HIV medical care. Subsequent sessions were conducted upon discharge from the narcology hospital over a 6-month period in community (e.g., parks, coffee shops) or clinic locations, agreed upon by the case manager and participant.

The LINC intervention was developed via adaptation of the Antiretroviral Treatment Access Study (ARTAS) intervention for use in the Russian setting and specifically with people who inject drugs (PWID).

The NCS-2 was a re-interview of 5,001 individuals who participated in the Baseline (NCS-1). The study was conducted a decade after the initial baseline survey. The aim was to collect information about changes in mental disorders, substance use disorders, and the predictors and consequences of these changes over the ten years between the two surveys. The collection contains three major sections: the main survey, demographic data, and diagnostic data.

In the main survey, respondents were asked about general physical and mental health. Questions focused on a variety of health issues, including limitations caused by respondents' health issues, substance use, childhood health, life-threatening illnesses, chronic conditions, medications taken in the past 12 months, level of functioning and symptoms experienced in the past 30 days, and any services used by the respondents since the (NCS-1). Additional questions focused on mental disorders including depression, bipolar disorder, specific and social phobias, generalized anxiety, intermittent explosive disorder, suicidality, post-traumatic stress disorder, neurasthenia, pre-menstrual dysphoric disorder, attention deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and separation anxiety. Respondents were also asked about their lives in general, with topics including employment, finances, marriage, children, their social lives, and stressful life events experienced in the past 12 months. Additionally, two personality assessments were included consisting of respondents' opinions on whether various true/false statements accurately described their personalities. Another focus of the main survey dealt with substance use and abuse, nonmedical use of prescription drugs, and polysubstance use. Interview questions in the NCS-2 Main Survey were customized to each respondent based on previous responses in the Baseline (NCS-1).

The middle section contains demographic and other background information including age, education, employment, household composition, household income, marital status, and region.

The last section of the collection focused on whether respondents met diagnostic criteria for psychological disorders asked about in the main survey.

The NCS-2 was a re-interview of 5,001 individuals who participated in the Baseline (NCS-1). The study was conducted a decade after the initial baseline survey. The aim was to collect information about changes in mental disorders, substance use disorders, and the predictors and consequences of these changes over the ten years between the two surveys. The collection contains four major sections: the main survey, demographic data, diagnostic data, and state, county, and tract FIPS data.

In the main survey, respondents were asked about general physical and mental health. Questions focused on a variety of health issues, including limitations caused by respondents' health issues, substance use, childhood health, life-threatening illnesses, chronic conditions, medications taken in the past 12 months, level of functioning and symptoms experienced in the past 30 days, and any services used by the respondents since the (NCS-1). Additional questions focused on mental disorders including depression, bipolar disorder, specific and social phobias, generalized anxiety, intermittent explosive disorder, suicidality, post-traumatic stress disorder, neurasthenia, pre-menstrual dysphoric disorder, attention deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and separation anxiety. Respondents were also asked about their lives in general, with topics including employment, finances, marriage, children, their social lives, and stressful life events experienced in the past 12 months. Additionally, two personality assessments were included consisting of respondents' opinions on whether various true/false statements accurately described their personalities. Another focus of the main survey dealt with substance use and abuse, nonmedical use of prescription drugs, and polysubstance use. Interview questions in the NCS-2 Main Survey were customized to each respondent based on previous responses in the Baseline (NCS-1).

The second part contains demographic and other background information including age, education, employment, household composition, household income, marital status, and region.

The third part focuses on whether respondents met diagnostic criteria for psychological disorders asked about in the main survey.

The fourth part contains respondents' state, county, and tract FIPS data.